Company intelligence / Profile preview
VBL Therapeutics
Modi’in, Israelvblrx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
VBL Therapeutics develops targeted therapies for immune-inflammatory diseases and solid tumors. Its lead immunology candidate, VB‑601, leverages a proprietary monocyte targeting technology to limit chronic inflammation and was expected to enter Phase I trials in late 2022. The company’s previous lead oncology program, VB‑111 (ofranergene obadenovec), a gene therapy for solid tumors such as recurrent glioblastoma and platinum-resistant ovarian cancer, reported disappointing results in a Phase III trial for ovarian cancer in July 2022. The company continues to advance its immunology pipeline while evaluating next steps for its oncology assets[1][3][5].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Gene therapyMonocyte-targeting biologics[1][3][5]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on VBL Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VBL Therapeutics.